TISSIUM CEO’s Vision Is To Make The Tissue Recon Label Stick
CEO Bancel Envisages TISSIUM As A Tissue Reconstruction Specialist Rather Than Simply A Provider Of A Technology
Christophe Bancel, CEO of French medtech innovator TISSIUM, has made a career in various parts of the health care products industry, identifying business opportunities, founding, directing and leading ventures, and planning for contingencies. The ex-Serono and UCB executive, who has had many other postings, is now testing his adaptability and leadership qualities by bringing a versatile class III synthetic polymer device into key markets.
You may also be interested in...
Connecting The Dots Between Diversity, Empowerment And Business Growth
Urmi Prasad Richardson brings a wealth of science and business experience to diagnostics and life sciences multinational Thermo Fisher Scientific, where for the past two years she has been president of the group’s vast and varied EMEA business. The Indian-born, Germany-based executive has surmounted a range of challenges along the way and offers her story as inspiration for others.
UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.
UK Pro-Innovation Report Offers Promise For Medtech With MHRA/NICE Alignment
Report to government underlines need for faster, parallel evaluation of medtech and healthtech innovation and recommends bigger role for MHRA alongside work done by approved bodies on UKCA file processing.